Published in Diabetes Week, February 12th, 2007
Metabolex investigators, presenting at the Keystone Symposium in Keystone, Colorado, compared the effect of MBX-102/JNJ-39659100, rosiglitazone and a vehicle treatment. MBX-102/JNJ-39659100 was previously referred to as metaglidasen.
Both mice and rats treated with either active compound demonstrated substantially reduced inflammation...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week